Targa Resources heads into September with an unusual split: analysts racing to upgrade price targets while short sellers rebuild positions at the fastest monthly pace in recent history.
The analyst community has turned decisively constructive. Wells Fargo lifted its target to $324 this week — a $42 increase — while maintaining its Overweight rating. That follows RBC Capital raising to $338 and Morgan Stanley moving to $343, both within the past two weeks. Jefferies sits at $345. The lone holdout is TD Cowen, which nudged its target to $275 but kept a Hold. The consensus mean of $310 implies only modest upside from the current $296 close, yet the direction of travel is uniformly upward. Bulls point to a diversified midstream asset base, rising capex, and a new CFO signalling operational focus. Bears flag the fossil-fuel transition risk and a projected net-debt/EBITDA around 3.75x as reasons for caution. The stock has gained 9.5% over the past month and 3.2% this week, broadly in line with peers — OKE rose 4.4% on the week, WMB gained 5.8%, and added 3.7%.
Positioning tells a more nuanced story. Short interest has climbed 27% over the past month to 2.4% of the free float — still low in absolute terms, but the pace of accumulation is the fastest stretch in the 30-day window available. The week-on-week change of 11.6% is notable: shorts added roughly 525,000 shares between late August and September 1. At the same time, the borrow market is almost entirely unlocked. Availability sits at 7,417% — more than 211 million shares remain available to lend against roughly 5 million currently borrowed. Cost to borrow is negligible at 0.39%, down 16% on the week. There is no squeeze pressure here. New shorts face a frictionless entry, which may partly explain why they keep coming despite the rising tape.
Options traders are only modestly more cautious than usual. The put/call ratio of 0.23 is just above its 20-day average of 0.21 — a z-score of 1.2, well within normal range. The PCR remains near the lower end of its 52-week band (0.14 to 0.48), so the options market still leans call-heavy. That skew is consistent with the bullish analyst tone rather than hedging into a specific catalyst.
The ORTEX short score of 35 is unremarkable, in the 50th percentile of the universe — squarely in the middle of the pack. The dividend factor score, at 97, is the standout on the factor dashboard, reflecting the strength of the income story relative to peers. EPS momentum over 30 days ranks in the 61st percentile. On valuation, EV/EBITDA has compressed slightly over the past 30 days to 12.6x while the PE has expanded modestly to 24.3x — a mix that suggests earnings are growing but the multiple is not being meaningfully re-rated.
Director selling has been visible but modest. Two directors — Charles Crisp and Waters Davis — made open-market sales totalling roughly $1.6 million in aggregate over late August, with no 10b5-1 plan attached. Net insider activity over 90 days is a negative 5,400 shares. Given the scale of those trades against the stock's overall float, and the fact that these are directors rather than C-suite, the signal is limited — more consistent with routine profit-taking near all-time highs than any conviction view on the outlook.
The next earnings date is November 5. The most recent print, in early August, produced a modest 1.2% one-day dip before recovering 2.6% over the following week — a pattern that suggests the stock absorbs earnings reasonably well even when the initial reaction is negative. With shorts quietly building and the Street still lifting targets, the key question heading into Q3 results is whether volume throughput numbers validate the capex story that has driven the analyst upgrades throughout the summer.
See the live data behind this article on ORTEX.
Open TRGP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
